)
Visual
test
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals (RYTM) investor relations material
Rhythm Pharmaceuticals Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate Presentation summary9 Jan, 2026
Strategic positioning and financial overview
IMCIVREE (setmelanotide) is available in over 25 countries, with a strong global commercial infrastructure and expanding indications for rare genetic obesity disorders.
Q4 2025 preliminary unaudited net revenues were approximately $57M, an 11% increase quarter-over-quarter, with FY 2025 revenues at ~$194M.
Cash, cash equivalents, and short-term investments totaled $416.1M as of September 30, 2025, sufficient to fund operations for at least 24 months.
Product pipeline and clinical development
Setmelanotide is advancing for acquired and congenital hypothalamic obesity, Prader-Willi syndrome, and additional rare MC4R pathway diseases.
Next-generation MC4R agonists, RM-718 (weekly injection) and oral bivamelagon, are in clinical development with patent protection into the 2040s.
Multiple clinical milestones are anticipated in 2026, including regulatory decisions, trial readouts, and pivotal trial initiations.
Market opportunity and patient impact
Significant market opportunities exist in acquired hypothalamic obesity (~10,000 US and EU prevalence each), Prader-Willi syndrome (~20,000 US, ~400,000 worldwide), and other rare genetic obesity disorders.
IMCIVREE is the first and only FDA- and EMA-approved therapy for early-onset, severe obesity and hyperphagia in Bardet-Biedl syndrome and certain genetic deficiencies.
Patient testimonials highlight transformative impacts on hunger and quality of life.
Initial acquired HO patient conversion expectations
Next-gen MC4R agonists' strategic importance
PWS trial data implications for broader use
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and robust acquisitions. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position.
Next Rhythm Pharmaceuticals earnings date
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb, 2026
Rhythm Pharmaceuticals
Next Rhythm Pharmaceuticals earnings date
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for rare genetic disorders related to obesity. The company’s primary area of focus is on conditions caused by impairments in the melanocortin-4 receptor (MC4R) pathway, which regulates hunger and body weight. Rhythm Pharmaceuticals aims to address unmet medical needs by developing targeted therapies that can help manage severe obesity and related symptoms in patients with specific genetic deficiencies. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage